WASHINGTON.NIAGA.ASIA – The US health adviser said Thursday that some Americans who received Moderna’s COVID-19 vaccine at least six months ago should get booster half dose to increase protection against Corona virus.
Advisor to the Food and Drug Administration (Food and Drug Administration/FDA) unanimously recommend injection booster for seniors, as well as younger adults with other health problems, occupations or those at risk from exposure to COVID-19.
The recommendations are not binding but are a powerful way to extend the United States campaign to millions of people in America. Many people who got their initial Pfizer shot at least six months ago have already had booster, after the FDA authorized its use last month. Those who receive booster are the same high-risk group that, according to FDA advisers, should receive booster Modern.
Nevertheless, there is no evidence that it is time to open the dose booster Moderna or Pfizer vaccines for everyone.
The coronavirus remains largely a threat to people who are not vaccinated. While being vaccinated has strong protection against severe illness or death from COVID-19.
Speaking of doses, the initial Moderna vaccination consisted of two injections of 100 micrograms. But Moderna says one injection of 50 micrograms should be enough to booster.
The agency gathered its experts to consider who should get booster and when for those who received Moderna and Johnson & Johnson injections earlier this year. Competent parties will discuss J&J on Friday.
The FDA will use its advisory recommendations in making the final decision on boosters from both companies. Although it is estimated that the decisions taken will still encounter obstacles in the future.
Next week, a panel convened by the Centers for Disease Control and Prevention will offer more specifics about who should get the shot booster.
Many US scientists. keep split about who needs booster and its purpose. Is the injection booster it is needed mostly for people who are at risk of severe illness or whether booster injections should be used to try to reduce milder infections as well.
The FDA panel grapples with whether Moderna presents enough evidence to support it booster low dose.
It is known that when the delta variant spiked in July and August, a Moderna study found people who had just been vaccinated had a 36% lower infection rate compared to those who had been vaccinated for longer.
Another study of 344 people found six months of booster injections restored virus-fighting antibodies to levels considered protective – and that includes a huge jump in antibodies that can target the delta variant. But it was a small study, and only about half of those people got the exact dosage range that would be offered under the campaign booster Modern.
“The data itself is not strong but is definitely heading in a direction that supports this vote,” said Dr Patrick Moore of University of Pittsburgh.
And some advisers are concerned that increasing (antibodies) at a lower dose might deprive people of some of the potential benefits of a full third dose of injection.
One very rare side effect of the Moderna and Pfizer vaccines is inflammation of the heart, especially among young men immediately after the second dose. One question that remains is whether another dose could trigger more cases. Studies booster Moderna can’t quite afford to see such a rare risk.
However, Israel started offering Pfizer boosters sooner than the US and to more of its population. Thursday, Dr. Sharon Alroy-Preis of the Israeli ministry of health told the FDA panel that after 3.7 million doses booster given, there is no sign that the additional injection is more risky.
Because Moderna’s vaccine is similar to Pfizer’s, FDA advisers found the data convincing.
Temporary booster Pfizer is only for certain high-risk groups of Americans, Israeli officials praised the wider use of boosters in their country to stem the surge in infections of the delta variant.
“There is no question in my mind that the breaking of the curve was due to dose booster,” said Alroy-Preis in response to an FDA adviser noting that other states have seen a decline in delta cases without use. booster extensively.
But FDA advisers have also highlighted one puzzling problem: people with severely weakened immune systems can already get a third full dose of the Moderna vaccine soon after the initial vaccination. So the question remains, do they have to qualify for a booster too, which will be their fourth dose?
Source : Associated Press
Editor : Saud Rosadi
